USING CDK INHIBITORS IN ADVANCED PROSTATE CANCER

被引：0
|
作者：
Pearson, R. [1 ,2 ]
Ng, J. [1 ,2 ]
Anantharaman, A. [2 ]
Pierro, L. [2 ,3 ]
Azam, H. [2 ,3 ]
Prencipe, M. [2 ,3 ]
机构：
[1] Univ Coll Dublin, UCD Sch Med, Dublin 4, Ireland
[2] Univ Coll Dublin, UCD Conway Inst Biomed & Biomol Res, Dublin 4, Ireland
[3] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2019年 / 188卷 / SUPPL 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
28
引用
收藏
页码：S331 / S332
页数：2
相关论文
共 50 条
  • [1] CDK inhibitors in hormone receptor positive advanced breast cancer
    Aktas, Bilge
    [J]. MARMARA MEDICAL JOURNAL, 2015, 28 (04): : 35 - 39
  • [2] Development of PARP inhibitors in advanced prostate cancer
    Bourlon, Maria Teresa
    Valdez, Paola
    Castro, Elena
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [3] Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
    Gong, Jun
    Posadas, Edwin M.
    Bhowmick, Neil
    Kim, Hyung L.
    Daskivich, Timothy J.
    Gupta, Amit
    Sandler, Howard M.
    Kamrava, Mitchell
    Zumsteg, Zachary S.
    Freedland, Stephen J.
    Figlin, Robert A.
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (03): : 119 - 125
  • [4] CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
    Wang, Xiao
    Chen, Hong
    Luo, Jun
    Xie, Liping
    [J]. EUROPEAN UROLOGY, 2020, 77 (03) : 342 - 343
  • [5] CDK4/6 inhibitors in advanced breast cancer, what is beyond?
    Mohammed, Amrallah A.
    Rashied, Hanaa
    Elsayed, Fifi Mostafa
    [J]. ONCOLOGY REVIEWS, 2019, 13 (02) : 125 - 133
  • [6] Cdk inhibitors in development and cancer
    Harper, JW
    Elledge, SJ
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) : 56 - 64
  • [7] Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer.
    Hupe, Marie C.
    Offermann, Anne
    Becker, Finn
    Joerg, Vincent
    Vogel, Wenzel
    Braegelmann, Johannes
    Perner, Sven
    Merseburger, Axel Stuart
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
    Neeb, Antje
    Herranz, Nicolas
    Arce-Gallego, Sara
    Miranda, Susana
    Buroni, Lorenzo
    Yuan, Wei
    Athie, Alejandro
    Casals, Teresa
    Carmichael, Juliet
    Nava Rodrigues, Daniel
    Gurel, Bora
    Rescigno, Pasquale
    Rekowski, Jan
    Welti, Jon
    Riisnaes, Ruth
    Gil, Veronica
    Ning, Jian
    Wagner, Verena
    Casanova-Salas, Irene
    Cordoba, Sarai
    Castro, Natalia
    Fenor de la Maza, Maria Dolores
    Seed, George
    Chandran, Khobe
    Ferreira, Ana
    Figueiredo, Ines
    Bertan, Claudia
    Bianchini, Diletta
    Aversa, Caterina
    Paschalis, Alec
    Gonzalez, Macarena
    Morales-Barrera, Rafael
    Suarez, Cristina
    Carles, Joan
    Swain, Amanda
    Sharp, Adam
    Gil, Jesus
    Serra, Violeta
    Lord, Christopher
    Carreira, Suzanne
    Mateo, Joaquin
    de Bono, Johann S.
    [J]. EUROPEAN UROLOGY, 2021, 79 (02) : 200 - 211
  • [9] PARP inhibitors in advanced prostate cancer: when to use them?
    Diaz-Mejia, Nely
    Garcia-Illescas, David
    Morales-Barrera, Rafael
    Suarez, Cristina
    Planas, Jacques
    Maldonado, Xavier
    Carles, Joan
    Mateo, Joaquin
    [J]. ENDOCRINE-RELATED CANCER, 2021, 28 (08) : T79 - T93
  • [10] PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers
    Mateo, Joaquin
    Carreira, Suzanne
    de Bono, Johann S.
    [J]. EUROPEAN UROLOGY, 2019, 76 (04) : 459 - 460
12345